- Home
- EYPT vs HTLD Comparison
EYPT vs HTLD Comparison
Compare EYPT & HTLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EYPT | HTLD |
|---|---|---|
| Founded | 1987 | 1978 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Trucking Freight/Courier Services |
| Sector | Industrials | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.2B |
| IPO Year | 2005 | 1995 |
Fundamental Metrics
Financial Performance| Metric | EYPT | HTLD |
|---|---|---|
| Price | $11.92 | $12.99 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 6 |
| Target Price | ★ $31.80 | $11.50 |
| AVG Volume (30 Days) | ★ 1.5M | 562.2K |
| Earning Date | 05-06-2026 | 04-23-2026 |
| Dividend Yield | N/A | ★ 0.60% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $7,539,000.00 | ★ $805,709,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3,115.57 | $8.36 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.41 | $7.00 |
| 52 Week High | $19.11 | $16.64 |
Technical Indicators
Market Signals| Indicator | EYPT | HTLD |
|---|---|---|
| Relative Strength Index (RSI) | 36.19 | 28.48 |
| Support Level | $9.65 | $12.23 |
| Resistance Level | $13.32 | $13.92 |
| Average True Range (ATR) | 0.81 | 0.54 |
| MACD | -0.23 | -0.24 |
| Stochastic Oscillator | 3.24 | 6.16 |
Price Performance
Historical ComparisonAbout EYPT EyePoint Pharmaceuticals Inc.
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.
About HTLD Heartland Express Inc.
Heartland Express Inc, along with its subsidiaries, operates as a short, medium, and long-haul truckload carrier and transportation services provider. It mainly provides nationwide asset-based dry van truckload service for shippers across the United States, along with cross-border freight and other transportation services offered through third-party partnerships in Mexico. The group operates under the brand names of Heartland Express, Millis Transfer, Smith Transport, and CFI (for services within Mexico).